^
    8d
    Best Practice PD-L1 Staining and Interpretation in Gastric Cancer Using PD-L1 IHC PharmDx 22C3 and PD-L1 IHC PharmDx 28-8 Assays, with Reference to Common Issues and Solutions. (PubMed, Biomedicines)
    Techniques are available that can optimize the automated staining of PharmDx PD-L1 assays using the Autostainer Link 48 to ensure consistent staining performance. The PD-L1 IHC PharmDx 22C3 and PD-L1 IHC PharmDx 28-8 assays show high concordance when used according to manufacturers' guidelines.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • PD-L1 IHC 28-8 pharmDx
    9d
    Clinicopathological Implications of Maspin, CD8, and PD-L1 Expression in Liposarcomas. (PubMed, Curr Issues Mol Biol)
    Despite low overall expression rates, PD-L1 could serve as a prognostic biomarker and a potential target for immunotherapeutic strategies in liposarcomas. Further studies are necessary to standardize PD-L1 assessment and explore effective immunotherapy approaches for these tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx • PD-L1 IHC 28-8 pharmDx
    11d
    Sarcomatoid carcinoma of the prostate - A single institution experience with emphasis on molecular genetic findings. (PubMed, Hum Pathol)
    This study sheds light on the molecular landscape of SCP, which may be valuable to elucidate the prognostic and therapeutic implications for this uncommon disease.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    13d
    Prognostic value of manual and digital PD-L1 expression in pT3 and pT4 colon cancer. (PubMed, Diagn Pathol)
    Our results suggest that high PD-L1 expression is associated with longer OS. In future studies examining PD-L1 expression as a prognostic biomarker in CC, assessing PD-L1 expression using a digital approach or the CPS can be recommended.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx
    14d
    PD-L1 expression in gastric cancer assessed with antibodies 28-8 and 22C3. (PubMed, Sci Rep)
    However, both assays demonstrated a concordance rate of 61%. In the study population, the subgroup with a Combined Positive Score (CPS) ≥ 10 was the most prevalent, suggesting that high PD-L1 expression is relatively common and potentially clinically relevant in this cohort.
    Observational data • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx • PD-L1 IHC 28-8 pharmDx
    16d
    DIAMOND: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=140, Recruiting, Queen Mary University of London | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk)
    17d
    Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Tumor mutational burden
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • etoposide IV
    21d
    Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China. (PubMed, J Comp Eff Res)
    The VENTANA PD-L1 (SP263) Assay, which can guide multiple immune checkpoint inhibitor monotherapies (e.g., atezolizumab and pembrolizumab) for advanced NSCLC patients, achieved a higher percentage of successfully diagnosed and treated, and a higher quality-adjusted life-year at a lower cost compared with Dako PD-L1 IHC 22C3 assay and Dako 22C3 antibody concentrate. The robustness of the base case results was confirmed by both one-way sensitivity analysis and probabilistic sensitivity analysis. The VENTANA PD-L1 (SP263) Assay is cost-effective compared with Dako PD-L1 IHC 22C3 assay and Dako 22C3 antibody concentrate for the immunotherapy treatment for advanced NSCLC patients in China.
    Journal • HEOR • Cost-effectiveness
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab)
    23d
    Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma. (PubMed, Cancer Immunol Immunother)
    Our real-life cohort analysis confirms the limitations of standalone biomarkers like PD-L1. We identified gene expression-based markers with strong prognostic and predictive value for ICI treatment outcomes.
    Clinical • Clinical data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • HLA-E (Major Histocompatibility Complex, Class I, E) • IRF7 (Interferon Regulatory Factor 7) • PSMB10 (Proteasome 20S Subunit Beta 10)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    30d
    Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2029 --> Jun 2030 | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    30d
    TaxRamPem: Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Emory University | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial primary completion date • Tumor mutational burden
    |
    PD-1 (Programmed cell death 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • docetaxel • Cyramza (ramucirumab)
    1m
    Comparison of PD-L1 expression in head and neck squamous cell carcinoma among preoperative biopsy, surgical resection and metastatic lymph node. (PubMed, Front Oncol)
    These findings suggest that PD-L1 expression varies in response to tumor microenvironment across various tumor areas and time frames. Therefore, individualized PD-L1 assessment for each specimen type is crucial for accurately determining eligibility for ICIs.
    Journal • IO Companion diagnostic • PD(L)-1 Biomarker • IO biomarker • PD(L)-1 companion diagnostic
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx